Itch and neuropathic itch

Junichi Hachisuka\textsuperscript{a,b}, Michael C. Chiang\textsuperscript{a,b}, Sarah E. Ross\textsuperscript{a,b,*}

Abstract
Neuropathic itch is a pathological condition that is due to damage within the nervous system. This type of itch can be severe and unrelenting, which has a very negative impact on quality of life. Neuropathic itch is more common than generally appreciated because most types of neuropathic pain have a neuropathic itch counterpart. Unfortunately, much like neuropathic pain, there is a lack of effective treatments for neuropathic itch. Here, we consider the neural basis of itch and then describe how injuries within these neural circuits can lead to neuropathic itch in both animal models and human disease states.

Keywords: Itch, Pruritus, Scratch, Neuropathic, Mouse, Human, Neuropathy

1. The sense of itch
Itch is a distinct sensation that provokes the desire to scratch and scratching typically causes itch to subside, at least temporarily. This itch-scratch sensorimotor response to an aversive agent is highly conserved across the animal kingdom: mammals itch, birds itch, even fish, although lacking appendages, will rub themselves against rocks (or use their tails) to scratch themselves. Whether insects itch is less clear, but flies show site-directed grooming behavior in response to the application of an irritant to the wing—a behavior that is likely due to itch. Of course, not all animals show itch behavior. For instance, rather than scratching an aversive agent away, worms will simply retreat to evade harm. Nevertheless, the high degree of conservation of itch-induced scratching across all vertebrates and some invertebrates implies that this behavior confers an important evolutionary advantage. So why do we itch?

Scratching an itch is believed to have at least 3 beneficial consequences. First, if the organism is able to detect a threat at the body surface, such as a disease-carrying parasite, it can be scratched away. In addition, because the sensation of itch is highly aversive, the organism learns from past experience to avoid future exposures. Finally, the very act of scratching can help recruit the immune system, helping rid the body of an infectious agent. Each of these responses is believed to favor survival by protecting an organism from harm, hence the conservation of itch/scratch as a sensorimotor response.

As an aversive sensation that serves to protect the body, itch is conceptually similar to pain. However, there are a few notable distinctions between these 2 percepts. Although pain can be triggered from almost anywhere in the body, itch is only experienced where scratching is possible—at the body surface.\textsuperscript{52} Itch and pain elicit distinct behavioral responses: one scratches an itchy stimulus but withdraws from a noxious one. Furthermore, itch and pain can be differentially modulated. For instance, although mu opioids such as morphine reduce pain, this class of analgesics causes itch.\textsuperscript{4} Finally, although they are both unpleasant, itch and pain are perceptually distinct sensations. These key differences imply that the neural circuits that give rise to itch must be distinct from those that give rise to pain. Understanding the coding of itch and how it is distinguished from pain in the nervous system remains a major unanswered question.

1.1. Neural basis of itch
Itch and pain are believed to be elicited by activity in primary sensory afferents that have a relatively slow conduction velocity (C-fiber and A\textsubscript{s} fibers).\textsuperscript{35,74} However, the specific afferents that mediate itch remain a matter of controversy. There are primary afferent fibers that respond to pruritogens (itch-inducing agents) such as histamine and whose activity corresponds to the sensation of itch in humans.\textsuperscript{82} It has thus been speculated that these fibers convey pruriception from the periphery to the nervous system, and these observations have been used to argue in favor of the existence of afferents that are selectively tuned for itch but not pain.\textsuperscript{51,77} Yet there are many observations, as described further below, that do not fit with this straight-forward explanation. As a result of these inconsistencies, it has been suggested that it is not simply the nature of the afferent but rather the pattern of activity from a given afferent or the combination of afferent activity from a population of afferents, which gives rise to either itch or pain.\textsuperscript{17,52}

1.2. Itch-selective afferents
Perhaps the strongest evidence for the existence of itch-selective primary afferents comes from studies in mice, where at least 2 distinct populations have been implicated in itch. One of these populations is the MrgrpA3-expressing population of unmyelinated afferents.\textsuperscript{49} Genetic labeling of these neurons reveals that they selectively innervate the superficial skin,
which would be predicted for itch-specific afferents. Moreover, selective activation of MrgrprA3-expressing afferents using a chemogenetic strategy is sufficient for itch behavior, whereas ablation of these cells reduced (but did not eliminate) itch in response to a variety of pruritogens. A second population that seems to be involved is neurons that express natriuretic polypeptide B (Nppb). Recent single-cell profiling experiments have revealed that the Nppb population of primary afferents also expresses receptors for several pruritogens, such as interleukin 31. Moreover, the Nppb- and MrgrprA3-expressing sensory neurons are nonoverlapping populations, and it is postulated that both of these afferent subtypes mediate itch.

The idea that 2 distinct populations of primary afferents mediate the response to pruritogens was predicted based on human studies, where it was long speculated that there are at least 2 different kinds of itch: histamine-induced itch and nonhistaminergic itch. Histamine is the main pruritogen that is responsible for hives (urticaria), and histamine in the epidermis causes a pure sensation of itch, together with wheal and flare, which are believed to be mediated by the local release of substance P and calcitonin gene–related peptide from primary afferents. Studies using microneurography to look at the activity of single primary afferents in humans have identified a population of mechanically insensitive C-fibers with large cutaneous innervation territories that fire vigorously in response to histamine with a duration and intensity of activity that matches the subject description of the itch percept. Thus, it is hypothesized that these afferents mediate histaminergic itch. By contrast, numerous pruritogens cause itch that is not associated with wheal and flare, and the absence of this axon-reflex is interpreted to indicate the involvement of nonpeptidergic afferents. This so-called nonhistaminergic itch has been elicited historically using cowhage (Mucana pruriens), a tropical plant whose seed pods are coated with short hairs called spicules. When cowhage spicules are inserted superficially into the skin, they cause a prickly itch that is mediated by a cysteine protease. Intriguingly, human microneurography experiments suggest that the primary afferents that respond to histamine and those that respond to cowhage are distinct. Consistent with the idea of at least 2 populations of itch-tuned afferents, in a cunning experiment using a lidocaine derivative that can only drive bilateral activity in supplementary motor area and the periaqueductal gray, it was shown that blocking the activity of histamine-responsive afferents in mice does not inhibit the response to a nonhistaminergic pruritogen.

1.3. Population coding

Although there is good evidence suggesting the existence of at least 2 populations of primary afferent that respond to itch-inducing agents, these findings do not yet fully solve the puzzle of how specificity is achieved. For instance, microneurography experiments in humans show that histamine-responsive afferents also respond to algogens such as bradykinin with a similar magnitude and duration, so it is hard to envision a mechanism through which they could signal only pruriception. The issue of specificity is also underscored by findings in monkeys in which the high prevalence of itch-responsive afferents (75% for histamine) does not fit with the idea that pruriception and nociception are mediated by distinct sensory neurons. Even in the mouse, where 2 populations of afferents (MrgrprA3 and Nppb) have been suggested to be itch-specific, it is not clear that all of the neurons in these populations signal itch and only itch. Finally, these 2 populations are not likely to be the only neurons that can signal itch because beta-alanine–induced itch is believed to occur through yet another nonoverlapping population: MrgrprA3-expressing afferents, which are a cutaneous population that is highly sensitive to mechanical stimuli. Because primary afferents that respond to pruritogens but not algogens have been elusive, many have speculated that the solution to the problem of sensory specificity must lay elsewhere, perhaps being encoded by activity at the population level together with differences in central connectivity.

1.4. Spinal circuits of itch

The primary afferents that convey pruriception from the periphery to the spinal cord target the superficial dorsal horn (lamina I and the outer region of lamina II). How this pruritogen input is integrated in these laminae is not yet clear. Several cell types in the dorsal horn are believed to be involved in mediating pruriception, including the neurons that express gastrin-releasing peptide (GRP) and those that express its receptor (GRPR). Ablation of GRP neurons gives rise to mice with decreased itch and increased pain behaviors. Moreover, inhibition of GRPR or ablation of the spinal neurons that express GRPR results in significantly decreased itch, with no changes in pain behaviors. These and other studies have raised the possibility that pruriception is conveyed from primary afferents to spinal projection neurons through a disynaptic pathway. However, the reality is likely more complex, and precisely how GRP- and GRPR-expressing interneurons fit into neural circuits that integrate pruriception within the spinal cord remains unclear.

The neurons that convey pruriception from the spinal cord to the brain are a subset of anterolateral tract neurons, which target numerous brain structures including the rostral ventral medulla, the parabrachial nucleus, the cerebellum, and the thalamus. However, the specific subset that is involved in conveying pruriception, as opposed to nociception, is not yet clear. Thus, although many groups have recorded from spinal (or trigeminal) output neurons that respond robustly to pruritogens, invariably such output neurons also respond to algogens. Because we lack a satisfactory model to explain how information sent from the spinal cord to the brain could be itch specific, many have concluded that the decoding of itch must occur within the brain rather than the spinal cord. And yet the scratch reflex, which likely represents an itch behavior, is a spinal reflex. Furthermore, the modality selective modulation of itch and pain by mu opioids is likely to occur at the level of the spinal cord rather than the brain. Indeed, morphine was found to decrease the activity of trigeminothalamic neurons that seemed to be tuned for nociception while increasing the activity in those that seemed tuned for pruritogen. These findings suggest that, although the exact circuitry remains elusive, spinal cord integration of sensory input is sufficient for the basic decoding of itch vs pain.

1.5. Supraspinal circuits of itch

The specific neural circuits in the brain that integrate itch also remain poorly characterized. In general, the cerebral areas that are activated in response to pruritic or noxious stimuli are similar, and include the thalamus, primary and secondary somatosensory cortices, anterior cingulate cortex, prefrontal cortex, amygdala, and periaqueductal gray (Fig. 1). However, a few differences have been reported. For instance, although noxious heat drove bilateral activity in supplementary motor area and the
subdivision of the lateral parabrachial nucleus and have been indicated in the generation of fear memory to foot shock through its projection to the central amygdala. Given the commonalities between itch and pain, it is likely that similar pathways mediate the aversive response to itch. Consistent with this possibility, inhibition of the parabrachial nucleus reduced pruritogen-evoked scratching behavior. The degree to which the same or different populations of neurons in the parabrachial nucleus mediate the aversive responses to pain and itch remains to be determined.

2. Neuropathic itch

When neurons (or glia) involved in integrating or conveying pruritception anywhere in the peripheral or central nervous system become damaged, neuropathic itch can ensue. This type of itch—neuropathic itch—is estimated to represent 8% of the total cases of chronic pruritus. Moreover, itch is likely an underdiagnosed symptom of neuropathic conditions. In some cases, neuropathic itch can be very severe, and unfortunately, there is a dearth of effective treatments, underscoring that neuropathic itch as an important unmet clinical need.

Almost every neuropathic pain syndrome has a neuropathic itch counterpart that affects a subpopulation of the afflicted patients. Thus, many individuals with neuropathic pain suffer from itch in addition to pain. Specifically, in patients with neuropathic pain, itch is a feature in one-third of cases, with moderate to severe itch observed in 5% to 10% of patients. There are other instances of neuropathic itch where itch is the prevailing symptom, which occurs in the absence of pain (eg, postherpetic itch). Why itch, rather than pain, is a prominent feature of neuropathic states in some cases but not others remains unclear.

2.1. Central sensitization of itch

Like its pain counterpart, neuropathic itch can be amplified or exacerbated within the nervous system through a group of mechanisms collectively termed central sensitization. Many people with neuropathic itch develop so-called “itchy skin” (alloknesis), a state in which innocuous touch or brush causes itch. This type of sensitization is conceptually analogous to touch-evoked pain (allodynia), which often accompanies neuropathic pain. Both alloknesis and allodynia are believed to be mediated by the abnormal integration of low-threshold mechanoreceptor input within the spinal cord. Sensitization can also occur to high threshold input, giving rise to hyperalgesia (abnormally elevated response to noxious stimuli) or hyperkinesia (abnormally elevated response to pruritic stimuli). Intriguingly, for patients with chronic pain, histamine is perceived as painful rather than itchy. Conversely, for patients with chronic itch, noxious stimuli can be perceived as itch inducing rather than painful. These findings suggest that there are parallel mechanisms of sensory amplification for itch and pain that are likely mediated by plasticity within the nervous system.

2.2. Peripheral neuropathies as a cause of neuropathic itch

The most common types of neuropathic itch are due to damage to primary afferents (Fig. 1), which can occur as a consequence of infection of primary afferents, compression of nerve fibers, metabolic diseases, or toxins that affect nerve fiber function, as well as rare genetic conditions.

Contralateral anterior cingulate cortex, intracutaneous histamine injections activated the ipsilateral supplementary motor area and contralateral anterior cingulate cortex. Another study reported similar motor regions as well as limbic areas such as the anterior insula cortex (aIC) as well as the left aIC exhibited connectivity with motor regions such as the basal ganglia and the amygdalae. Such differences between itch and pain may be due, at least in part, to distinct motor plans that are triggered in response to either pruritceptive or nociceptive stimuli. Different types of itch (histaminergic and cowhage-induced) also activate similar patterns of activity within the brain. However, it has been reported that only cowhage-induced itch resulted in activity within the contralateral insula and claustrum. Thus, conventional itch and pricky itch have somewhat distinct representations in the brain.

Itch, like pain, is believed to have multiple dimensions, including discriminative and affective components. It is likely that the spinothalamic tract mediates discriminative aspects of itch, whereas cerebral pathways conveying the affective aspects of itch may be mediated by evolutionarily ancient circuitry. In this regard, it is likely that the spinoparabrachial pathway, which projects to the lateral parabrachial nucleus, plays a critical role. The lateral parabrachial nucleus is believed to serve as an alarm system, warning the organism of potential threats. Using a clever strategy, Rodriguez et al. genetically labeled the neurons in the parabrachial nucleus that responded to a noxious stimulus and showed that activation of this population was sufficient to drive affective behaviors, including aversion and vocalization. One population of neurons that is likely involved in this response are those expressing calcitonin gene–related peptide, which are localized within the external lateral
One of the main causes of severe neuropathic itch is shingles (herpes zoster). This disease occurs on reactivation of latent virus that remains in nerve cells after an infection of chickenpox (varicella zoster). Typically, one ganglion is affected, resulting in a painful rash in the corresponding dermatome. Although the immune system may clear the active virus within a few weeks, there is often long-term damage to the primary afferents that result in pain (postherpetic neuralgia) or itch (postherpetic itch) in the region of skin that is innervated by the damaged fibers. These symptoms can be severe and persistent, lasting for months or years. It is estimated that 30% of people with postherpetic neuralgia suffer from itch, and for reasons that are poorly understood, itch is more likely to be observed in proximal dermatomes (head and face) than in distal dermatomes.67,71

Occasionally, compression of nerves can cause very severe itch, which is typically localized to the region of skin that is innervated by the damaged nerve. These itch-associated conditions commonly include brachioradial pruritus due to damage to cervical (C3-C6) nerves, resulting in itch on the arms, and notalgia paraesthetica due to entrapment of dorsal rami of thoracic (T2-T6) nerves, resulting in itch on the back.92 With these 2 conditions, itch is often the prevailing symptom. Although pain is a more common symptom, it is possible for itch to occur on damage to almost any cutaneous nerve, resulting in itch that is typically accompanied by tingling and numbness within the innervated skin.

Generalized nerve fiber degeneration can also give rise to itch. This type of polyneuropathy can occur from uncontrolled diabetes mellitus, exposure to chemotherapeutic drugs, or alcohol abuse.50 In these cases, primary afferents with longer axons, such as those that innervate distal tissues, are believed to be the most vulnerable, often resulting in itch of the feet. One-third of patients with peripheral neuropathies are estimated to suffer from itch.7

Finally, there are rare instances when neuropathic itch is caused by a genetic disorder. For instance, with Fabry disease, an X-linked disorder caused by loss-of-function of α-galactosidase, there is an accumulation of a glycolipid that exerts toxic effects in several cell types, including peripheral nerves.53 As a consequence of this nerve damage, individuals with Fabry disease often experience itching, numbness, tingling, burning, pain, and cold sensitivity. A second, rare genetic cause of neuropathic itch is due to a variant in SCN8A, which encodes a voltage-gated sodium channel that is expressed in sensory neurons.19,91 In particular, the I739V variant gives rise to a sodium channel with slower inactivation kinetics. Although most people with this variant have small fiber neuropathy with paroxysmal pain, in some people, this variant causes attacks of itch rather than pain. The neuropathic itch in these individuals can be precipitated by warm and spicy food, suggesting a possible involvement of TRPV1.

2.3. What causes neuropathic itch due to peripheral neuropathies?

Irrespective of the underlying cause, one of the hallmarks of peripheral neuropathic itch that distinguishes it from inflammatory itch in nerve density: neuropathic itch is typically associated with a decrease in the density of nerve fibers that innervate the epidermis, whereas inflammatory itch is associated with increased cutaneous innervation.54,71 Indeed, in a famous case of postherpetic itch, only 5% of epidermal nerve fibers remained leading some to speculate that central mechanisms must be involved.68 The idea that fewer fibers could give rise to more itch is somewhat counterintuitive. Nevertheless, it is clear that activity within these afferents plays an essential role in neuropathic itch because of peripheral neuropathies since transient inhibition of this input with topical lidocaine alleviates itch.65 The degree to which this type of itch is due to pathological activity in the remaining afferents vs an abnormal pattern of sensory input that is aberrantly integrated by the central nervous system is unknown.

2.4. Peripheral neuropathic itch: insight from animal models

All primary afferents use glutamate as an excitatory neurotransmitter (and some also release peptides, such as substance P and calcitonin gene–related peptide).30,101 With the goal of blocking glutamate release from these sensory neurons, 2 different groups selectively removed the vesicular glutamate transporter type 2 (VGLUT2) in either all or in subsets of primary afferents.32,50 Because VGLUT2 is the only glutamate transporter in most high-threshold afferents and therefore required for glutamatergic neurotransmission, it was not surprising that mice lacking VGLUT2 in these cells showed reduced responses to noxious mechanical, thermal, and chemical input. Unexpectedly, however, these mice also showed spontaneous itch behavior and elevated responses to pruritogens. Thus, decreased pain was associated with increased itch. These findings underscore the idea that itch can occur as a result of an abnormal pattern of activity in populations of primary afferents.

2.5. Central lesions as a cause of neuropathic itch

Although rare, central lesions can also result in neuropathic itch (Fig. 1). These include tumors or strokes such as those affecting the lateral medulla.64 Prion disease, such as Creutzfeldt–Jakob disease, can present with pruritus particularly for patients with the familial Creutzfeldt–Jakob disease because of a mutation in the gene-encoding prion protein (PRNP).14 Intriguingly, Scrapie, another prion disease found in sheep and goats, is so named because affected animals scrape themselves against objects to relieve itch.42 Tumors, abscesses, or lesions that affect the spinal cord can also result in pathological itch in the corresponding region of skin. For instance, when vascular malformations (cavernous hemangiomas) occur in the spinal cord, neuropathic itch can ensue.3,15,46 The underlying cause of itch with these vascular malformations is not clear but could involve either loss of inhibition or ectopic activity because of gliosis and hemosiderin deposition.20

Demyelinating disorders can cause short attacks of itch over many regions of the body. In patients with multiple sclerosis, the incidence of itch is low (~5%); however, one- to two-thirds of patients with neuromyelitis optica report pruritus, which precedes other neurological symptoms.22,29,54 Neuromyelitis optica is a relapsing neuroinflammatory disease of the central nervous system that is associated with aquaporin-4 autoantibody.47 Aquaporin-4 is expressed in astrocytes of the white and gray matters along the whole spinal cord with markedly higher intensity in the superficial lamina of the dorsal horn.65 Magnetic resonance imaging revealed that itch in these patients corresponded to the level of spinal lesion.61

2.6. Central neuropathic itch: insight from animal models

As observed in humans, pathological changes within the dorsal horn in animal models can result in neuropathic itch. Specifically, cell death in the dorsal horn because of intraspinal injections of the excitotoxic agent quisqualate results in both elevated
responses to noxious stimuli as well as abnormal biting and licking behavior that is suggestive of itch.\textsuperscript{20,100} Similarly, ablation or inhibition of glycinergic neurons in the dorsal horn results in both elevated pain and itch behaviors.\textsuperscript{2,4} One of the glycinergic subtypes that may be involved in the inhibition of itch is that can be genetically tagged with the NPY-Cre allele because ablation of these cells resulted in spontaneous itch behavior and increased mechanically induced itch.\textsuperscript{8}

Mice lacking the transcription factor Bhlhb5 (also known as Bhlhe22) develop self-inflicted skin lesions because of excessive licking and scratching\textsuperscript{79,81} that is now recognized to be due to severe neuropathic itch. This conclusion was based on a series of studies from our laboratory, first showing that Bhlhb5 mutant mice showed dramatically enhanced itch behaviors in response to a variety of pruritogens.\textsuperscript{79} Next, through a combination of conditional ablation and fate mapping approaches, we provided evidence that the abnormal itch in Bhlhb5 mutant mice is due to the loss of a specific population of inhibitory neurons in the dorsal horn that require Bhlhb5 for survival.\textsuperscript{79} We called these cells B5-I neurons because they are inhibitory neurons that express Bhlhb5 during development and require Bhlhb5 for survival. Critically, we showed that transient inhibition of B5-I neurons causes spontaneous scratching behavior.\textsuperscript{37} These findings suggested that one of the normal functions of B5-I neurons is to inhibit itch.\textsuperscript{100} (Fig. 2).

Most recently, we discovered that B5-I neurons differentiate into 2 subsets of inhibitory neurons in the dorsal horn: those that express neuronal nitric oxide synthase and those that express dynorphin.\textsuperscript{12,37} The dynorphin population is particularly attractive as a population that inhibits itch because dynorphin is a kappa opioid receptor agonist, and there is strong precedent for the involvement of kappa agonists in the inhibition of itch.\textsuperscript{32,40,97} Furthermore, our work revealed that kappa opioid receptor tone at the level of the spinal cord bidirectionally modulates itch: intrathecal kappa agonists inhibit itch, whereas intrathecal kappa antagonists exacerbate itch.\textsuperscript{37} Together, these findings suggest that dynorphin-expressing inhibitory interneurons in the superficial dorsal horn function to inhibit itch, and that mice lacking these cells develop severe neuropathic itch that is central in origin.\textsuperscript{12} (Fig. 2). Consistent with this idea, the transplantation of inhibitory interneurons into the dorsal horn can reverse the neuropathic itch in Bhlhb5 mutant mice.\textsuperscript{6,9}

2.7. Treatments for neuropathic itch

As of yet, there have been no clinical studies to test putative therapies for neuropathic itch. Given the similarities in the neural circuits of itch and pain, many treatments for neuropathic pain have been tried on people suffering from neuropathic itch, and there is abundant anecdotal evidence that many of the treatments, such as capsaicin patches and gabapentin, may also be partially effective for the treatment of neuropathic itch in some cases. However, a key difference between itch and pain that should be underscored is that mu opioid receptor agonists such as morphine exacerbate and even trigger itch rather than alleviate it.\textsuperscript{4} In this regard, it is interesting to speculate that distinct opioids may be involved in modulating distinct aspects of somatosensation. In particular, the inhibition of itch by kappa agonists may be a counterpart of the inhibition of pain by mu agonists. The kappa agonist nalfturafine is used clinically for the treatment of uremic pruritus and cholestatic pruritus in Japan.\textsuperscript{16} Whether the kappa agonists will similarly prove effective for the treatment of neuropathic itch remains unknown.

Conflict of interest statement

The authors have no conflict of interest to declare.

The authors of this publication were supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number R01 AR063772 to S. E. Ross, as well as the National Institute of Neurological Disorder and Stroke under Award Number NS02372925 to S. E. Ross and by NIH Grants F30NS096860 and to M. C. Chiang.

Acknowledgments

We thanks M.S. Gold for his helpful suggestions.

Article history:
Received 13 December 2017
Accepted 21 December 2017
Available online 2 January 2018

References


\[6\] Basbaum AI, Braz JM. Cell transplants to treat the "disease" of neuropathic pain and itch. PAIN 2016;157(suppl 1):S42–7.


Oklinski MK, Skowronski MT, Skowronska A, Rutzler M, Norgaard K, Oaklander AL, Cohen SP, Raju SV. Intractable postherpetic itch and

Oaklander AL. Mechanisms of pain and itch caused by herpes zoster


Oaklander AL, Cohen SP, Raju SV. Intractable postherpetic itch and cutaneous deafferentation after facial shingles. PAIN 2002;96:9–12.


